GNPX News and Press, Genprex Inc. From 01/13/21

Genprex ([[GNPX]] +0.4%) has passed the final release tests of scaled-up clinical grade production to supply REQORSA immunogene therapy for upcoming Acclaim-1 and Acclaim-2 trials in non-small cell lung cancer.The company recently announced the completion of the techn...

Company passes final release tests of scaled-up clinical grade production to supply drug product for upcoming Acclaim-1 and Acclaim-2 clinical trials in lung cancer Genprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX ), a clinical-sta...

Proceeds will add resources for the Company’s Acclaim-1 and Acclaim-2 clinical trials in lung cancer, as well as its pre-clinical programs in cancer and diabetes Genprex, Inc. (Nasdaq: GNPX) (“Genprex” or the “Company”), a clinical-stage ge...

Gainers: Air T (AIRT) +156%.FAT Brands (FAT) +85%.Addex Therapeutics (ADXN) +72%.Senseonics Holdings (SENS) +57%.SIFCO Industries (SIF) +45%.Gevo (GEVO) +44%.Neoleukin Therapeutics (NLTX) +42%.Avinger (AVGR) +41%.IZEA Worldwide (IZEA) +23%.Harvest Capital Credit (HCAP) +20%.Losers: Jagua...

Lizhi (LIZI) +29%.Ekso Bionics Holdings (EKSO) +25%.AgEagle Aerial Systems (UAVS) +22%.ENGlobal Corporation (ENG) +23%.Supernus Pharmaceuticals (SUPN) +23%.Scopus BioPharma (SCPS) +21%.Mogo (MOGO) +18%.Magnite (MGNI) +18%.Kopin Corporation (KOPN) +18%.Magna International (MGA) +18%.InMed Phar...

Genprex ([[GNPX]] +11.1%) inks agreement with a single healthcare-dedicated institutional investor for the purchase and sale of ~3.12M shares at a purchase price of $3.85/share in a registered direct offering priced at-the-market.No warrants will be issued in connection with the tra...

The clinical-stage micro-cap, Genprex (GNPX), is up +13.6% after the company announced the completion of manufacturing scale-up for its lead product candidate, REQORSA™ immunogene therapy targeting non-small cell lung cancer.Subject to passing final testing currently und...

Genprex, Inc. (Nasdaq: GNPX) (“Genprex” or the “Company”), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into a securities purchase agreement with a si...

Gainers: Ocugen (OCGN) +90%, NantHealth (NH) +35%, Organovo (ONVO) +25%, Genprex (GNPX) +23%, Spero Therapeutics (SPRO) +14%.Losers: Soligenix (SNGX) -54%, SOS (SOS) -39%, Venus Concept (VERO) -23%, BioCryst Pharmaceuticals...

Major Manufacturing Milestone Positions the Company for Success In the Lung Cancer Therapeutics Market, expected to grow to $26.3 Billion by 2023 Achievement Highlighted by Important Process Improvements and Significantly Improved Economies of Scale Genprex, Inc. ...